RecruitingObesity & Overweight
A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
Eligible age
18–55 yrs
Accepts
Women
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A multi-center, randomized, placebo-controlled, double-blinded (within cohorts), Sponsor-unblinded, Phase 1b study to explore the safety, pharmacokinetics, and pharmacodynamics of CX11 tablets in participants with obesity or overweight with weight-related comorbidities.
Sponsor: Corxel Pharmaceuticals
You may qualify if…
- ✓ Male or female, 18-55 years.
- ✓ BMI ≥30.0 to ≤39.9 kg/m², or ≥27.0 to \<30.0 kg/m² with at least 1 weight-related comorbidity: prediabetes, hypertension, dyslipidemia, or obstructive sleep apnea.
- ✓ Prior unsuccessful diet/exercise weight-loss attempt and stable body weight within 90 days.
- ✓ Able to comply with study procedures and reproductive requirements.
You may not qualify if…
- ✕ Diabetes or obesity due to endocrine/genetic causes.
- ✕ Recent weight-loss drugs, GLP-1-based therapy, glucose-lowering drugs, obesity surgery/device, or investigational treatment.
- ✕ Significant cardiovascular, ECG/QT, pancreatic, gallbladder, GI, liver, kidney, thyroid, psychiatric, malignant, infectious, autoimmune, or lab abnormality risks.
- ✕ Personal/family history of medullary thyroid carcinoma or multiple endocrine neoplasia.
- ✕ Pregnancy, breastfeeding, recent nicotine/drug use, excessive alcohol use, or any condition/medication making participation inappropriate.
Where it's recruiting
Source: ClinicalTrials.gov · NCT07652047 · last updated 2026-06-17